Thanks Jonzo!
Hadn't seen that one before.
Here back at you
re: rvx-297
http://molpharm.aspetjournals.org/content/92/6/694
" RVX-297 suppressed EAE pathology when administered to mice either prophylactically or therapeutically. In addition, the production of multiple cytokines in vivo (Fig. 7) and ex vivo (Table 6) was suppressed by RVX-297. In vivo efficacy was comparable or superior to that of the S1P1 agonist FTY720 (fingolimod), an approved therapeutic agent for the treatment of MS."